It is estimated that somewhere between 34 and 61 million people in
the US are obese and in much of the developing world incidence is
increasing by about 1% per year. Associated with obesity is a
two-fold increase in the incidence of type 2 diabetes. Breaking
the link between the two conditions could represent an advance and
a number of candidate targets have been overviewed in recent
TherapeuticAdvances bulletins. A dossier has now been produced to
analyze this area in greater detail. Special attention has been
placed on those targets with exceptional proof of concept and
which may be able to reduce not only the risk of diabetes but also
heart disease and in some cases cancer. This dossier:
> Overviews the connection between obesity and diabetes and
identifies candidate targets including PPAR-gamma, Adiponectin,
Resistin, TNF, IkappaB kinase, iNOS, Leptin & Protein Kinase
C-theta.
> Analyzes molecules in development that target insulin
resistance
> Offers a strategic analysis of which candidate targets may
be of greatest potential
> Suggests screening architectures to develop therapeutic
candidates
> Offers practical input to help expedite the screening
process focussing on novel HTS/MTS assays designed to reduce bench
to clinic down-time and assays using human material to fully
characterize the clinical potential of hits
Dossier statistics: 5,482 words, plus profiles on 6 drugs in
development and on-line access to over 50 citations, 3 PaperSets
(these are targeted bibliographies covering entire areas) and
knowledge resources.
Publication date: 4th December 2001
About the Author: Dr Jon Goldhill has over 10 years of academic
and industrial research experience including 5 years in middle
management at the French pharmaceutical giants, Sanofi-Synthelabo.
Focussing on a variety of indications including inflammatory
disorders, GI disease, Urological conditions and cancer, Dr
Goldhill was responsible for target identification and project
development. Dr Goldhill is now CEO and chief analyst at
LeadDiscovery and coordinates the identification of candidate drug
discovery projects with industrial potential.
Price: $150.00
